11 August 2020 - The pan-Canadian Oncology Drug Review evaluates new cancer drugs for public funding recommendations. 

While pCODR's deliberative framework evaluates overall clinical benefit and includes considerations for exceptional circumstances, rarity of indication is not explicitly addressed. 

Given the high unmet need that typically accompanies these indications, Keech and colleagues explored the impact of rarity on oncology HTA recommendations and funding decisions.

Read International Journal of Technology Assessment in Health Care article